Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement

Heart and Vessels

Volumn 25, Issue 3, 2010, Pages 182-186

  Fukushima, Kenichi ^a   Kobayashi, Yoshio ^a   Kitahara, Hideki ^a   Iwata, Yo ^a   Kuroda, Nakabumi ^a   Ooyama, Masayuki ^a   Nomura, Fumio ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiplatelet therapy; Clopidogrel; Stent; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL;

AGED; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG EFFICACY; EPISTAXIS; FEMALE; HUMAN; HUMAN CELL; JAPANESE; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY ARTERY DISEASE; FEMALE; HEMORRHAGE; HUMANS; JAPAN; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956168813     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-009-1190-x     Document Type: Article

References (23)

1. Gawaz M, Seyfarth M, Müller I, Rüdiger S, Pogatsa-Murray G, Wolf B, Schömig A (2001) Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol 87:332-336 (Pubitemid 32144877)
2. Müller I, Seyfarth M, Rüdiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M (2001) Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85:92-93 (Pubitemid 32973418)
3. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112:2946-2950
4. Fukushima K, Kobayashi Y, Okuno T, Nakamura Y, Sakakibara M, Nakayama T, Kuroda N, Miyazaki A, Shimizu Y, Komuro I (2007) Incidence of side-effects of ticlopidine after sirolimuseluting stent implantation. Circ J 71:617-619
5. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, Maida R, Collins M, Kreps E, Moses JW (1999) Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99:2364-2366
6. Asano T, Kobayashi Y, Fukushima K, Iwata Y, Kitahara H, Ishio N, Kuroda N, Komuro I (2008) Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome. Circ J 72:1707-1708
7. Fukushima K, Kobayashi Y, Kitahara H, Iwata Y, Nakayama T, Kuroda N, Ooyama M, Nomura F, Komuro I (2005) Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement. Circ J 72:1282-1284
8. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246-251
9. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45:1392-1396
10. Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, Moretti C, Meliga E, Cuisset T, Alessi MC, Montalescot G, Collet JP, Di Sciascio G, Waksman R, Testa L, Sangiorgi G, Laudito A, Trevi GP, Sheiban I (2007) Metaanalysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 100:1199-1206
11. Gladding P, Webster M, Ormiston J, Olsen S, White H (2008) Antiplatelet drug nonresponsiveness. Am Heart J 155:591-599
12. Angiolillo DJ, Guzman LA, Bass TA (2008) Current antiplatelet therapies: benefits and limitations. Am Heart J 156(2 suppl):S3-9
13. Fukushima K, Kobayashi Y, Kitahara H, Iwata Y, Kuroda N, Ooyama M, Kuwabara Y, Nomura F, Komuro I (2009) Antiplatelet effect of 50-mg maintenance dose of clopidogrel evaluated by ADP-induced platelet aggregation compared to 200-mg ticlopidine: a preliminary study. Heart Vessels 25:41-44
14. Maree AO, Fitzgerald DJ (2007) Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115:2196-2207
15. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, Von Beckerath N, Schömig A, Schömig E (2004) Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 92:311-316
16. Heestermans AA, van Werkum JW, Schömig E, ten Berg JM, Taubert D (2006) Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites. J Thromb Haemost 4:1143-1145
17. Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL (2009) Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 30:1744-1752
18. Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, Eddy SM, Dostalik J, Mount J, Azuma J, Fujio Y, Jang IJ, Shin SG, Bleavins MR, Williams JA, Paulauskis JD, Wilner KD (2008) Pharmacokinetics/ genotype associations for major cytochrome P450 enzymes in native and first-and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 84:347-361
19. Brackbill ML, Kidd RS, Abdoo AD, Warner JG Jr, Harralson AF (2009) Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Heart Vessels 24:73-78
20. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107:32-37 (Pubitemid 36070929)
21. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ (2003) Lack of adverse clopidogrelatorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108:921-924
22. Siller-Matula JM, Lang I, Christ G, Jilma B (2008) Calciumchannel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52:1557-1563
23. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J (2008) Infl uence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256-260